Premium
ArQule Inc (ARQL)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm PR Newswire NEW YORK, Jan. 6, 2020 NEW YORK, Jan. 6, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities...
SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc. PR Newswire NEW YORK, Dec. 12, 2019 NEW YORK, Dec. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary...
- ARQ 531 demonstrates substantial anti-tumor activity and manageable safety profile - Eight of nine evaluable CLL patients initially dosed at ≥65 mg experienced a Partial Response (PR) - Five of...
(ARQL) Alert: Johnson Fistel Investigates Proposed Sale of ArQule, Inc.; Is $20 a Fair Price? PR Newswire SAN DIEGO, Dec. 9, 2019 SAN DIEGO, Dec. 9, 2019 /PRNewswire/ -- Shareholder rights law...
Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies Merck (NYSE: MRK), known as MSD outside the United States...
Conference call and webcast with ArQule management to be held on Monday, December 9, 2019 at 8:15 a.m. EST ArQule management to hold an Investor Event on Monday, December 9, 2019 from 8:00-10:00...
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London...
ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profile A total of 10 patients experienced partial responses (PRs) as of July 19th, the...
Conference call scheduled today at 9:00 a.m. ET ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2019. For the quarter ended September 30, 2019, the...
Data from a phase 1 clinical trial suggest that circulating tumor DNA (ctDNA) may serve as a reliable biomarker of tumor mutational status and could be used to predict treatment response...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
